<SEC-DOCUMENT>0001564590-15-000833.txt : 20150223
<SEC-HEADER>0001564590-15-000833.hdr.sgml : 20150223
<ACCEPTANCE-DATETIME>20150223170840
ACCESSION NUMBER:		0001564590-15-000833
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20150223
DATE AS OF CHANGE:		20150223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		15640550

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>abio-424b4_20150223.htm
<DESCRIPTION>424B4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<!-- NG Converter v3.0.3.5 -->
<body>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-weight:bold;">Prospectus Supplement No. 30</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(to Prospectus dated May 30, 2013)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed pursuant to Rule 424(b)(4) <br>Registration No. 333-187508 </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:13.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">125,000 Shares of Series A Convertible Preferred Stock </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12,500,000 Shares of Common Stock Underlying the Preferred Stock </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants to Purchase up to 6,250,000 Shares of Common Stock and </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6,250,000 Shares of Common Stock Underlying the Warrants </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201502232153317125057.jpg" title="" alt="" style="width:172px;height:59px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;This prospectus supplement supplements the prospectus dated May 30, 2013 (the &#8220;Prospectus&#8221;),<font style="font-family:Calibri;"> </font>as supplemented by that certain Prospectus Supplement No.&#160;1 dated July&#160;17, 2013 (&#8220;Supplement No.&#160;1&#8221;), by that certain Prospectus Supplement No.&#160;2 dated July&#160;19, 2013 (&#8220;Supplement No.&#160;2&#8221;), by that certain Prospectus Supplement No.&#160;3 dated July&#160;24, 2013 (&#8220;Supplement No.&#160;3&#8221;), by that certain Prospectus Supplement No.&#160;4 dated July&#160;30, 2013 (&#8220;Supplement No.&#160;4&#8221;), by that certain Prospectus Supplement No. 5 dated August 6, 2013 (&#8220;Supplement No. 5&#8221;), by that certain Prospectus Supplement No. 6 dated September 4, 2013 (&#8220;Supplement No. 6&#8221;), by that certain Prospectus Supplement No. 7 dated September 23, 2013 (&#8220;Supplement No. 7&#8221;), by that certain Prospectus Supplement No. 8 dated October 29, 2013 (&#8220;Supplement No. 8&#8221;), by that certain Prospectus Supplement No. 9 dated November 6, 2013 (&#8220;Supplement No. 9&#8221;), by that certain Prospectus Supplement No. 10 dated November 13, 2013 (&#8220;Supplement No. 10&#8221;), by that certain Prospectus Supplement No. 11 dated November 21, 2013 (&#8220;Supplement No. 11&#8221;), by that certain Prospectus Supplement No. 12 dated December 5, 2013 (&#8220;Supplement No. 12&#8221;), by that certain Prospectus Supplement No. 13 dated January 8, 2014 (&#8220;Supplement No. 13&#8221;), by that certain Prospectus Supplement No. 14 dated February 10, 2014 (&#8220;Supplement No. 14&#8221;), by that certain Prospectus Supplement No. 15 dated February 12, 2014 (&#8220;Supplement No. 15&#8221;), by that certain Prospectus Supplement No. 16 dated February 18, 2014 (&#8220;Supplement No. 16&#8221;), by that certain Prospectus Supplement No. 17 dated March 3, 2014 (&#8220;Supplement No. 17&#8221;), by that certain Prospectus Supplement No. 18 dated March 20, 2014 (&#8220;Supplement No. 18&#8221;), by that certain Prospectus Supplement No. 19 dated May 13, 2014 (&#8220;Supplement No. 19&#8221;), by that certain Prospectus Supplement No. 20 dated June 9, 2014 (&#8220;Supplement No. 20&#8221;), by that certain Prospectus Supplement No. 21 dated August 13, 2014 (&#8220;Supplement No. 21&#8221;), by that certain Prospectus Supplement No. 22 dated August 18, 2014 (&#8220;Supplement No. 22&#8221;), by that certain Prospectus Supplement No. 23 dated November 12, 2014 (&#8220;Supplement No. 23&#8221;), by that certain Prospectus Supplement No. 24 dated December 1, 2014 (&#8220;Supplement No. 24&#8221;), by that certain Prospectus Supplement No. 25 dated December 10, 2014 (&#8220;Supplement No. 25&#8221;), by that certain Prospectus Supplement No. 26 dated December 11, 2014 (&#8220;Supplement No. 26&#8221;), by that certain Prospectus Supplement No. 27 dated December 30, 2014 (&#8220;Supplement No. 27&#8221;), by that certain Prospectus Supplement No. 28 dated February 4, 2015 (&#8220;Supplement No. 28&#8221;), and by that certain Prospectus Supplement No. 29 dated February 17, 2015 (&#8220;Supplement No. 29&#8221;, and together with Supplement No. 1, Supplement No. 2, Supplement No. 3, Supplement No. 4, Supplement No. 5, Supplement No. 6, Supplement No. 7, Supplement No. 8, Supplement No. 9, Supplement No. 10, Supplement No. 11, Supplement No. 12, Supplement No. 13, Supplement No. 14, Supplement No. 15, Supplement No. 16, Supplement No. 17, Supplement No. 18, Supplement No. 19, Supplement No. 20, Supplement No. 21, Supplement No. 22, Supplement No. 23, Supplement No. 24, Supplement No. 25, Supplement No. 26, Supplement No. 27, and Supplement No. 28, the &#8220;Supplements&#8221;),<font style="font-size:12pt;"> </font>which form a part of our Registration Statement on Form S-1 (Registration No.&#160;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and the Supplements with the information contained in our current report on Form 8-K, filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on February 23, 2015 (the &#8220;Current Report&#8221;).  Accordingly, we have attached the Current Report to this prospectus supplement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible Preferred Stock (&#8220;Preferred Stock&#8221;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;This prospectus supplement should be read in conjunction with the Prospectus and the Supplements. This prospectus supplement updates and supplements the information in the Prospectus and the Supplements.  If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the information in this prospectus supplement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;Our common stock is traded on the Nasdaq Global Market under the trading symbol &#8220;ABIO.&#8221; On February 23, 2015, the last reported sale price of our common stock was, rounded to the nearest penny, $0.70 per share. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;<font style="font-weight:bold;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; beginning on page 5 of the Prospectus and beginning on page 22 of our quarterly report on Form 10-Q for the period ended September 30, 2014 before you decide whether to invest in shares of our common stock.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;<font style="font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The date of this prospectus supplement is February 23, 2015</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br></p>

<hr style="page-break-after:always">
<p style="text-align:justify;margin-bottom:0pt;margin-top:1pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): February 23, 2015 (February 18, 2015)</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Charter)</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road, Suite 140, Westminster, CO 80020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices) (Zip Code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(720) 940-2200</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';font-size:10pt;"><font style="font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';font-size:10pt;"><a name="OLE_LINK9"></a><font style="font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';font-size:10pt;"><font style="font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';">&#163;</p></td>
<td valign="top" style="width:96.67%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Wingdings 2';font-size:10pt;"><font style="font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;3 &#8212; Securities and Trading Markets </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.01.</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;18, 2015, ARCA biopharma, Inc. (&#8220;ARCA&#8221;) received a notice (the &#8220;Notice&#8221;) from The Nasdaq Stock Market (&#8220;NASDAQ&#8221;) indicating that ARCA&#8217;s common stock (the &#8220;Common Stock&#8221;) does not meet the continued listing requirement as set forth in NASDAQ Rule 5550(a)(2) based on the closing bid price of the Common Stock for the preceding 30 business days. The minimum closing bid price required to maintain continued listing on The Nasdaq Capital Market is $1.00 per share. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under NASDAQ Rule 5810(c)(3)(A), ARCA has a 180 calendar day grace period from the date of the Notice to regain compliance by meeting the continued listing standard. The continued listing standard will be met if the Common Stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If ARCA does not regain compliance within the 180 calendar day grace period, it will be afforded an additional 180 calendar day compliance period, provided that on the 180<font style="font-size:7.5pt;"><sup style="font-size:85%; vertical-align:top">t</sup><sup style="font-size:85%; vertical-align:top">h</sup></font> day of the first grace period ARCA (i)&#160;meets the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement) based on ARCA&#8217;s most recent public filings and market information and (ii)&#160;notifies NASDAQ of its intent to cure this deficiency. If ARCA does not indicate its intent to cure the deficiency or if it does not appear to NASDAQ that it would be possible for ARCA to cure the deficiency, ARCA would not be eligible for the second 180 day compliance period, and its securities would then be subject to delisting from the Nasdaq Capital Market. If ARCA is unable to regain compliance during the first 180 calendar day grace period or, if applicable, the second 180 day compliance period, and receives a delisting determination from NASDAQ it may, at that time, request a hearing to remain on The Nasdaq Capital Market, which request will ordinarily suspend such delisting determination until a decision by NASDAQ subsequent to the hearing. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that ARCA will be successful in maintaining its listing of the Common Stock on The Nasdaq Capital Market. This could impair the liquidity and market price of the Common Stock. In addition, the delisting of the Common Stock from a national exchange could materially adversely affect the ARCA&#8217;s access to capital markets, and any limitation on market liquidity or reduction in the price of the Common Stock as a result of that delisting could adversely affect ARCA&#8217;s ability to raise capital on terms acceptable to ARCA, or at all.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>

<hr style="page-break-after:always">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: February 23, 2015</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VP, Finance and Chief Accounting Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g201502232153317125057.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201502232153317125057.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_[@`.061O8F4`9``````!_^$+\$5X:68`
M`$U-`"H````(``<!$@`#`````0`!```!&@`%`````0```&(!&P`%`````0``
M`&H!*``#`````0`"```!,0`"````%````'(!,@`"````%````(:':0`$````
M`0```)H```#&`2P````!```!+`````$``$%D;V)E(%!H;W1O<VAO<"`W+C``
M,C`Q,SHP-3HR,R`Q,CHU.#HS,@```Z`!``,````!__\``*`"``0````!````
MK:`#``0````!````.P`````````&`0,``P````$`!@```1H`!0````$```$4
M`1L`!0````$```$<`2@``P````$``@```@$`!`````$```$D`@(`!`````$`
M``K$`````````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M
M``Q!9&]B95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+
M"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+`"``P$B``(1`0,1
M`?_=``0`"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!
M`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1
M`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R
M@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2
M!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+2
M1)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`Z_+ZEFY>0YM%CZJFDMK;68<8
M]NYQ;[G.=]+8GKKSGC<,FZ"USOYQWYOTNZAA5L<X[PW;),EVWOXK29?.593N
MV,K(#C`ESH]SWK`Q1EF/NY<DKG+A`!_PO\&+<D1'TQB-`YEOV^OC)ND`$_I'
M:3Q*U>B]0NRZ[*[_`'6TD>_C<TS$_P`KVJ.6*K*R9!]Q&K@UI(_//YSW(70A
M&3D\?19Q\7*?`)X>;A".0RQY+L$\7Z$IQ_Z*V9$\1)`!B[2P/K']:&=%S>FX
MI#2,N[]9<Z?T>/\`S1NT^B[U[*O^MLO6^=!/'FO/.IOZ;U[HW6>H69E`RLJP
M.Z=2^UH<,?#W5TL]-SM[?MGZY?\`^A2V&J^AA8OUCZEUKI6/;U#$JQLC#QZ]
M]U5KGLMT/O=6]H?4YK6[?T>Q/]4>J_M7H&+D.)-S&^A?//J5^PN/_&-V6_VT
MOKE_XE^I_P#A=R2FGTOJOUKZMT^OJ.-3T^JJ[=Z55C[BXAKG5^^UE>VKW,_T
M=RL?5SZT,ZS;DX=^.["ZCA$C(QG.#QH36Y]-S=OJ-;8W:[VK&^K_`-:NE=$^
MJV$W/]=I:+=A;38YECO4L?Z=%^S[.]^W_A5=^JG0<RCJ&;U_J&RK(ZF7&K%K
M>+!74]_K?I+F?H[K715_-?H_^W$E.EU_ZRX?16U5O8_*S<H[<7"H$VV$^WO[
M:Z]SOIO0ZA]<,AGJV68'3W'5N,*[<HM_D6Y/KX3'._>]*E8'0IZE_C"ZGE9/
MN=@MLKQP?S0QPQ6;?['KN_\`0A=T!`24\]T[J_7V==_8_6L?'8VVA]^+EXQ?
MLL]-U;7U[+MVRQC;?TE>]=#V4'45/L9:]C7652:WD`N;N&U^QWYNYJJ]8ZG5
MTGI>5U&X;F8M9?LXW.'\W4#^];9MK24YM7UG99];K.@0WTF4@MM$[CD#]-;1
M,[-C<9S'?\9ZBZ!>9]:9C]+P.B]2Q<VC,ZIT^YUF?Z5C7OLLR'?:LEVVMVYS
M/7]6G_BKUZ/BWU9-%>32[?5<UME;O%KAO8?\TI*?_]#J<:XTW.!.QS7N!,`D
M$$Z:_G+0<<3(BRP%MNUQW->0XM:/8VUWYSW_`+RN9G1L7+L-I+JK#])S#S_6
M:9:@CZOU#_M1;X?F_P#D5C1Y+FL1E",8Y<=W'B,?RE\LFT<N.5&S&5-;(RV,
MJ].KV,`]H[$'6'[MWZ5O^D4_J^2Z[*>!#88-.)]SD4_5Z@G6^T_YO_D5H8N)
M3BU"FENU@U.LDD\N<[\YREY?E>8/,1RY>&$<=\,8F]X\'#_5CZEL\F/@,8V3
M+<N%]=.LU8G3ATVK)93G=4>W$J+G`&MEI%61E']QE-3G^_\`TOIK7QNF]-Q\
M>JFFBH54,;77[6F&L&QOOC]T(61A=%9D#U<*E]^:\M<[T6N+S&YWJOV_FL;^
M>CV5=/PL!U9J97A5L+74L9+-COIM]&MI]KMWT=BU&N\5]5^H8?0?K1U/H5V3
M4W&OMW8KB\;19]-E.Z=K;'8]C*OZ^,NA^NV3C5?5?J`MM8SU*2RO<X#<YQAC
M6?O.>M%O1>BBKTA@8PK(^AZ+-L?U=J=W2.D.=6YV%CN=0P5TN-3#L8V=M=<M
M]C&[OHM24\[]6<3IO6_J13TRVQEDBQK]A!?58+;'UV;?I,LJ]EG_`*C53ZG]
M=?TC)M^JW7+646XKMN'8]P:TCEN.QS_\&]OZ;"_X+]7_`,"NN;T[I6+:[,KQ
M*:KF-,W,J:'[8]S=S&[_`,U1&+TOJ-;,NW%JN]:L!K[JFEQ9])C3Z@+MFN[8
MDIY/JE5_U7^M!^L;*W7='S@6YSZQN-1?MWO<&[O9ZM==['_\=5_HEV>'F8N;
MCLR<.YF118)9;6X.:?[35*G'QJ*6X]%;*J6#:RI@#6`?NM8WVJA9]6/J]8]U
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M>&V6;0_<UM=;/2]:QWYGJ*UEWW#)Q<6NW9:\A]I`'T&1O^EN_G7_`*)C=O\`
MY[5IGV7[19Z?I_:('J;=OJ1^;ZGY_P#G*7Z#UA]#UMNG&_9/^=Z>Y)3F=1SL
M@6Y+:7^F<<,90QL;K<BWW5MU_P`$QOYO_&_Z)$ZFX6WX^*^STZ@'9.208+64
M[2QV[_CRQ7C]F]=N[9]HVG;,>IM[[?S]BH5^C^U,K[;Z>[]#]GWQ&SW[/3W_
M`.$]?U-R2D5M^6_H=5=Q/VS-`I$@-,/ESGV!O\WLQ1ZEO[B/1D&@YES["_"Q
MV,VD`1N:TNN%&W_![?29_P`9O5VWT-/6V=]N^/`^IMW?R/IIA]E^R:>G]EV:
M?1]/9'_;?I[4E-''RKLGJ#*O5`;4TV75L@MW.'Z''W_2L]-FZRZSZ'\VGJ.7
ME9>4&9!KQZ7MK8Y@;J]GON8W>'>S_!6_RU=J^S;CZ.S=#=VR)VQ^B^A^9_HT
M2OT]OZ/;MD_1B)GW_1_E_224Y.?G7,R;138?1H9L<Q@$NOM@8^/5NW?I_P`]
MW^C8B=.OR'76B_(%C<:MM=T`;3<WW7/9^?MK^A_PEBO?JT_X.=_\G^=C_P`^
MJ57V>'^CLC<?4V1]/\_U-OY_[R2G,9U"W+R<>NJT5,M(N<UI!(I'\TU[M?TV
M4_\`,9_,U+7`A`H^Q2W[/Z4[?9Z>WZ$_F[?\'O5A)3__V?_M$(I0:&]T;W-H
M;W`@,RXP`#A"24T$)0``````$``````````````````````X0DE-`^T`````
M`!`!+`````$``0$L`````0`!.$))300F```````.`````````````#^````X
M0DE-!`T```````0````>.$))3009```````$````'CA"24T#\P``````"0``
M`````````0`X0DE-!`H```````$``#A"24TG$```````"@`!``````````$X
M0DE-`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8`````
M``$`,@````$`6@````8```````$`-0````$`+0````8```````$X0DE-`_@`
M`````'```/____________________________\#Z`````#_____________
M________________`^@`````_____________________________P/H````
M`/____________________________\#Z```.$))300(```````0`````0``
M`D````)``````#A"24T$'@``````!``````X0DE-!!H``````T4````&````
M```````````[````K0````@`:0!M`&$`9P!E`#``,``T`````0``````````
M```````````````!``````````````"M````.P`````````````````````!
M`````````````````````````!`````!````````;G5L;`````(````&8F]U
M;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````
M3&5F=&QO;F<``````````$)T;VUL;VYG````.P````!29VAT;&]N9P```*T`
M```&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S
M;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N
M=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N
M=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````
M````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````````
M``!"=&]M;&]N9P```#L`````4F=H=&QO;F<```"M`````W5R;%1%6%0````!
M````````;G5L;%1%6%0````!````````37-G951%6%0````!```````&86QT
M5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q4
M97AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!
M;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R
M=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC
M94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*
M;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````
M"W)I9VAT3W5T<V5T;&]N9P``````.$))3001```````!`0`X0DE-!!0`````
M``0````!.$))300,``````K@`````0```(`````L```!@```0@````K$`!@`
M`?_8_^``$$I&248``0(!`$@`2```_^T`#$%D;V)E7T--``+_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``L`(`#`2(``A$!`Q$!_]T`!``(_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#K\OJ6;EY#FT6/JJ:2VMM9AQCV[G%ON<YWTMB>NO.>-PR;H+7._G'?
MF_2[J&%6QSCO#=LDR7;>_BM)E\Y5E.[8RL@.,"7.CW/>L#%&68^[ER2N<N$`
M'_"_P8MR1$?3&(T#F6_;Z^,FZ0`3^D=I/$K5Z+U"[+KLKO\`=;21[^-S3,3_
M`"O:HY8JLK)D'W$:N#6DC\\_G/<A="$9.3Q]%G'Q<I\`GAYN$(Y#+'DNP3Q?
MH2G'_HK9D3Q$D`&+M+`^L?UH9T7-Z;BD-(R[OUESI_1X_P#-&[3Z+O7LJ_ZV
MR];YT$\>:\\ZF_IO7NC=9ZA9F4#*RK`[IU+[6APQ\/=72STW.WM^V?KE_P#Z
M%+8:KZ&%B_6/J76NE8]O4,2K&R,/'KWW56N>RW0^]U;VA]3FM;M_1[$_U1ZK
M^U>@8N0XDW,;Z%\\^I7["X_\8W9;_;2^N7_B7ZG_`.%W)*:?2^J_6OJW3Z^H
MXU/3ZJKMWI56/N+B&N=7[[65[:O<S_1W*Q]7/K0SK-N3AWX[L+J.$2,C&<X/
M&A-;GTW-V^HUMC=KO:L;ZO\`UJZ5T3ZK83<_UVEHMV%M-CF6.]2Q_IT7[/L[
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M)3FU?6=EGUNLZ!#?292"VT3N.0/TUM$SLV-QG,=_QGJ+H%YGUIF/TO`Z+U+%
MS:,SJG3[G69_I6->^RS(=]JR7;:W;G,]?U:?^*O7H^+?5DT5Y-+M]5S6V5N\
M6N&]A_S2DI__T.IQKC3<X$['->X$P"003IK^<M!QQ,B++`6V[7'<UY#BUH]C
M;7?G/?\`O*YF=&Q<NPVDNJL/TG,//]9IEJ"/J_4/^U%OA^;_`.16-'DN:Q&4
M(QCEQW<>(Q_*7RR;1RXY4;,94ULC+8RKTZO8P#VCL0=8?NW?I6_Z13^KY+KL
MIX$-A@TXGW.13]7J"=;[3_F_^16ABXE.+4*:6[6#4ZR23RYSOSG*7E^5Y@\Q
M'+EX81QWPQB;WCP</]6/J6SR8^`QC9,MRX7UTZS5B=.'3:LEE.=U1[<2HN<`
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M&OV$%]5@ML?79M^DRRKV6?\`J-5/J?UU_2,FWZK=<M91;BNVX=CW!K2.6X['
M/_P;V_IL+_@OU?\`P*ZYO3NE8MKLRO$IJN8TS<RIH?MCW-W,;O\`S5$8O2^H
MULR[<6J[UJP&ONJ:7%GTF-/J`NV:[MB2GD^J57_5?ZT'ZQLK==T?.!;G/K&X
MU%^W>]P;N]GJUUWL?_QU7^B79X>9BYN.S)P[F9%%@EEM;@YI_M-4J<?&HI;C
MT5LJI8-K*F`-8!^ZUC?:J%GU8^KUCW6G`H:YQEY8T,W'Q>*MF]W]9)36S?K+
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MQ:[=EKR'VD`?09&_Z6[^=?\`HF-V_P#GM6F?9?M%GI^G]H@>IMV^I'YOJ?G_
M`.<I?H/6'T/6VZ<;]D_YWI[DE.9U'.R!;DMI?Z9QPQE#&QNMR+?=6W7_``3&
M_F_\;_HD3J;A;?CXK[/3J`=DY)!@M93M+';O^/+%>/V;UV[MGVC:=LQZFWOM
M_/V*A7Z/[4ROMOI[OT/V??$;/?L]/?\`X3U_4W)*16WY;^AU5W$_;,T"D2`T
MP^7.?8&_S>S%'J6_N(]&0:#F7/L+\+'8S:0!&YK2ZX4;?\'M])G_`!F]7;?0
MT];9WV[X\#ZFW=_(^FF'V7[)IZ?V79I]'T]D?]M^GM24T<?*NR>H,J]4!M33
M9=6R"W<X?H<??]*STV;K+K/H?S:>HY>5EY09D&O'I>VMCF!NKV>^YC=X=[/\
M%;_+5VK[-N/H[-T-W;(G;'Z+Z'YG^C1*_3V_H]NV3]&(F??]'^7]))3DY^=<
MS)M%-A]&AFQS&`2Z^V!CX]6[=^G_`#W?Z-B)TZ_(==:+\@6-QJVUW0!M-S?=
M<]GY^VOZ'_"6*]^K3_@YW_R?YV/_`#ZI5?9X?Z.R-Q]39'T_S_4V_G_O)*<Q
MG4+<O)QZZK14RTBYS6D$BD?S37NU_393_P`QG\S4M<"$"C[%+?L_I3M]GI[?
MH3^;M_P>]6$E/__9.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@
M`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`
M<P!H`&\`<``@`#<`+@`P`````0`X0DE-!`8```````<`"`$!``$!`/_A$DAH
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTG
M[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\/V%D;V)E
M+7AA<"UF:6QT97)S(&5S8STB0U(B/SX-"CQX.GAA<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&%P=&L](EA-4"!T;V]L:VET(#(N."XR+3,S
M+"!F<F%M97=O<FL@,2XU(CX-"@D\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B('AM;&YS
M.FE8/2)H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\B/@T*"0D\<F1F.D1E
M<V-R:7!T:6]N(&%B;W5T/2(B('AM;&YS.GAA<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O;6TO(CX-"@D)"3QX87!-33I$;V-U;65N=$E$/F%D
M;V)E.F1O8VED.G!H;W1O<VAO<#HP,3DY8V1F92UC,S8Y+3$Q93(M.#=F-2TX
M-S`U,#$Y9C$R.&8\+WAA<$U-.D1O8W5M96YT240^#0H)"3PO<F1F.D1E<V-R
M:7!T:6]N/@T*"3PO<F1F.E)$1CX-"CPO>#IX87!M971A/@T*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\/WAP86-K970@96YD/2=W)S\^_]L`
M0P`!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`@("`@("`@("`@(#`P,#`P,#`P,#_]L`0P$!`0$!`0$!`0$!`@(!`@(#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M_\(`$0@`.P"M`P$1``(1`0,1`?_$`!X```$#!0$!``````````````@'"0H`
M`@0%!@,!_\0`,1```0$(`@$"!0,$`P```````0(`$0,$!08'"!()(3$R$"!!
M(A-"%`HC%A<8%3<9_\0`'@$``P`"`P$!`0````````````$"!P@#!08)"@3_
MQ`!!$0`!!`$#`P($`P0'!0D````"`0,$!081$@<`(1,Q""(R%!5!419A0B,)
M$(%2,T,D%R!Q@E,8D:%B-$0E-289_\0`/!(``0,"!`,%!@4"!04``````1$A
M`@`Q05$2`V%Q!/"!D2(%H;'!,A,&$-'A%`<@8O%"<B,54H(S)#3_V@`,`P$`
M`A`#$````)2GR]V#'#3S(W4^NZKD_-]R=/T-P8X3O7B6ZQNAMQ!&O8RBDIP^
MS;<]$%8QP2'Q-[,GMF-W,<43O%'+_.'O,??T.P2K&4/-(/KY[9`L*^W?-^X^
MI'GR*%B*28-PJ5&#![7D(KD5+%)CF(EFTT@)Q2E"9!D3FQ4EPDC^?GPW+,S=
MO#U=/V*@95\P(.G&5'KOMWJLV=8+E)N27+Q'&'1X6U+00PN-!^1'F*T;*`)V
MX2-7)6".%^<3>@R=ML2*=EOS0^:W>]Y/JNT>R^Y^HL=^W(LAPNG,MUN.-+>H
MM1B()5=*-L.7,`T@@-,*84@<<(U*9$Q'M/LC"_JWDK<\W\^G.4U-W<1=UG_Q
MXZT&/0(B.S1Q9/7.N['PZE?FP6%ULTKCCAZHDDAF#0I'@5\1\%:*ZGIQMQ(*
M&SM4\P0]`2P`DZ<`4\&JXIKO24V=*;)@-*8WTLJ@H*"@L`6AZUFD1LPV;0IR
MB=#!*U#77DXP]@,?AD`(6*3IL/(904%!04&(3:/YQQ9?(-U4I<PHJFYGQNI,
MT>,+S*]'&-1M)NYG_]H`"`$"``$%`-F=O+JD;NHV8<_W"R[SV*7)1<SY^HE3
MU/VHJ>71#*E(8*#?1N2&+V]Q(<WAB4D<@&"@?@20SW_"0H\U<USXTQK+4VD4
M.D8\NF1S!B*9$QK+2XU(V;AN;R]020>2CY++)*(G+\G%2F<YO"F]&"B@O>P!
MY$%`4X?#&_[*8N_,\C5K@PO8NP,A2K/RNN%.V=KS&E$[4H5R3Q"B')*?'P5]
MJ5%7(J8?>`2M/Q))`3Q9)`#5F1KUFWOB?-)E54C+=A(E\HYB-?@ZJ0ZK6-C@
MDN_'S``>OB]0X!4,K0MY42E"2"&/A1!#$.8_D407L`2'$*X^<^ZDV=F.H2G7
M_E6G,=`LO)EE=?>2YJ8P3K]:N":+#!2%(/'P6>YD@)92$DN#GK!XI9/VL0&*
M7@!S#PWJWZ7!B`6*$E@E(;BGX$/"N!!"`7E_J>)0Q!20]1<SPMGH9S)XD^7J
M#A]?F!>?1B4N"@&)402D%)2R@DIY>"OF"62DN"T1`"".2%J\*'S'T^J7.5[8
M?N2T3T/J7N4[BGVJ]8OJMS_U)]K?_]H`"`$#``$%`,=8KEY^0F*#8<`?\?C\
MQ9:U;%GX60L=1+<'A[%X)#?0^"7!C[V`!;P6'%3>7>7O(2?5JG.?M9"KUN+&
MB1YVL2<>WKGAS$;(<:--X_\`O*0\L"0"E3R%`N"F(#$>/1E!X^U1(>WAB"Q"
M@7$%J^A<:F6XJ4_NFM69.F;H*H::A>/]+'P)<%<3R`)(5\/1@0XN>`%I/(L2
M\^A<'ASP]+%P^$BF4K-&N*UXDRM5'N&83:UN&3BY,,M2[(27A/,I>2Q*0?/)
M*%.)\#BA0>&"1Q^OD!SU*/C[V',-^,\;,R-4;5$3-U#F5',5N<QFVC0A==YU
M"[9GDL,I+V\."B"/!X<6'-X\,'@`K!]6)Y,1R8E1)#TE[W%[>C$/;B`S@][F
M^Q_H?)4EZF`2$*`+.<0"&/J[SY#.>H.)!2[P_P"5X`_45*"O+!1<7*8*200`
M2A*0``S@`?4.200EAQ>0I3`$?/\`4>UO#0VB>Y7J/3]88,'<X?H/:'?'_]H`
M"`$!``$%`-E=Q+U7=E&R/L774Q;DV)@TZJY4V*MV>U/VOK63JI#B)B)4M*!N
MAV'8XTVO^7B+6FNS%1E:;G3NFFM4ZECOLNSSF.R=9.V#6W8C*:)J$J'MWV`Z
MRZ34BW-S.PG+]%SQW"[!:;JQQ>TGD>RHZN$+(G8/86/]^(1)AM:]!CUNY+'Q
M[3Z+(T6AV16*=DW$\62E-=J4BE[+2S^*XL!$3LJL:ZMUL6=7^RB]IM)ON6W\
MFJ!"@83T&"(FC/=52)^<[9]M]B*5JEK1TGZ_5G<;/,&55^//N$K!V)Q)KIC*
MK86PA?M\6]8%C;L6+G"'8&`<TT#8/#;8XB4\7!EN3J9Q#8N?:9)6_?R8T]:.
M%9B2C[-07`=KNP]R:_ZE63:^PUHZ9]`.5+OP'LO!4"C^32N&,)W3=7:1K3UF
M]'%-U@SQ;G?91JC4^M_^/%5*%-:#@``HAJ9?`0^Y+(-ZW=9NZ]&V>VETZ_CG
M;+1KVPNT*:J-FWGBS+LG2(DID&Q:4G)F4$5J%K)-5*Y]DJI4Z?3)2E;%XBWH
M[G%1Y:+"[:)ZA:;=KN"MB<+;&X\_DMY0Q]6K'ZY\@XKR;H?L+862NDCL0I&0
M]5.Q/6K5*^\M]%VT^/<@V3DVU]PMY==M*;"ZY,ZW5>&F?75F+'>\78_-U"7E
MH=1RSCWK![LO\]85_P`<9]U&MG,=2D="LN2,/_2#,'[:-H+E*<F<!ZWVC@BF
MY>P=B?.]LS?7YU^58(M:B2E`HG7!H=2C8>C6I&*[MH?7#H10%V'HWJ)B7(&5
M,)X)V)H5I:+ZA6%?=Z8[L?)%`5U/Z/2<Y:/65HM9]3R!I[K'E6CPNO+225KE
M]XYL_)MGTSKHT6H\O_YB:`F&4A0"0&5#0IOPPPW!/*NS\G2:?K)DJQZ+5L^9
M(QQ1;0JMPV3@K'UB91I5]3%Z[4&U\JS]^VXBP-6,E6/BG'MPW71;0I=E9GI-
M\W?5MKL<4JNUW,MLVU8<MMSC":G<:9>HF5J9D;.]DXSI]`K,Q6J)\JP"-M9&
M\*KA:Q<7Q:W7K^MV_KYV/SK;57BY8PA9U?LR'8,C?F6<69OQY<4YAFW[+FLD
MW!DFH991F[52UKJM7'.O&-*W)W5L?:MZ9.-;L3(U.CV#:EX8GUU_LO*ER2\K
M^4R_S1W./#DESH3N>W?[W_7O$'_4B>+X/'\T7WGVPG.C\64[\B?:M_-'M;__
MV@`(`0("!C\`G_'G\52C#HH;9&]UNW(QF=V*K';W"`D01Y3#S2(3S"0%=4/3
M/Y6^Y3N[6X82C+?F"?,`2/*A.2$J"J"XZ3J]K^5ON./UYRA'_P!J2$A"D5%X
MQ(,E%B$K]MU/\I?<<]W8))CN=0@.@V/ETZ3)`=2%QG76_:G\@='L=#]Z]/(1
MV`!,?N-L#YI:B?.4&IX@R1%5HF822/0%`HQ**6&+YD*BIG>AFG8]]#+V]V%2
MU&0"@+I.-K8YCVF@B:2>S.@YI1T@H`[/X<.QI[4NH`.Y7+AXT$DDN(PY@G&A
MJ".GZX-9,US%$1<!0O%>&3@\17&@!$$$%#9QP<\>6=+V]OX;NQL];+;W?WFZ
M`820I]7<`UF1241C$`:4!1B:Z[[H]0EL]'U>V=B.YN;LHCI]W9GN1A(;8!$1
MO?3U[9E+ZD9*2=)KTZ/H_3=5L^D>C=7O3V-S?CKVM\KIA`[T24$0`9-+6#:*
M&O7NM]']/)],ZB$AO]3*48;.V"=0^@J?41?,<9B5A$2/V!T?5]9M]5]4[\#)
MR1]/I]V<#%P$#Q*@@ZB0;44BCOSQ[8AZB@_0UN*-1`!!XACVQ#6H&/RE_:X_
M4=P2KA#[OSJ4B0$!P7N7!>&*/<UN:)"Y]Y]N:LR!*A)$DG@^#(7P*#C:B=1.
M/Q5&\+(U&1A$S7D"%O\`DWP(:E`4DY_G;V9WKYB3Q"'M[[T`C=O&A.()F$4E
MRC.40.Z@!$LE%'_+/(_AUXV_39]3U$>HZ@F.L1U"._.0CK*1B0A<A\E(KZ/2
M>G?M-[TKJ_WG5]%TV^.IZS<Z<1(W9;FW#Y0%,X`$2F$1)$K/H?M_I=OJ_3^O
M^E^RZ0++J9;LQ';D.IVC")C&04ZH@DS.G3EM>E>H=,.NW.FZ,2ZCIOW<H;G2
MRD\83Z8I,@K'3-2@`*1TU_'.WT/I\]F`EU$5,A(?_'N-8R!D`P,BZ/)%J,C\
MR!?!:`T`NA<@\`$>^"HB\JU&_"W@"E,9%!8YE%\"4+D+P_`G5I</DIOA9>ZI
MPTP,P;N,2Y=!;(B_>LI@2`1\%1%#<$S[ZE$24H;!3=+>Q,ZC(`V1W*BZE2J<
M/Z)1$<&/'C[[C@:^F'5!P/Q][40%\K'O+*B@'@2P[_PZWTOK]K_C_4(]7O&>
MU(Z=S2=XSC(*%(,0"$<KJ2NB]%W/5=J/2['^]UF_]*0ZKJH;<M<.FD5F#M[A
M(@(@Z5U+$DUZ5]U=-]O^D=!U?6=3U,=Z?3]-MQW=C:,!]&6WN)&6W.!F9I"(
M)D"KFOH>K].3ZST,YPZ3?VI$[O414@3ZZ>X#([@B`5$AB@""OL3U*'3C=Z+I
M3O'=W(C4(&6S**2DX`$V)*R=D!,@08\.SGVFIQN`7#FY7E>]Z"!#^;U`Z5D,
M$%@+K@&4`>&<I2(0"ZL`GY48$J2.7)S9T'8UJ,6,CR?XE??7EB/IE=3HI8`@
M8G`#+-*):4%-G;+GG[J@TB+`J6LNK#`(<EXK:E+#M;,T$VT"'ARM@F?.@C@`
M\3Q.?@`*CI0E;XA7]E!0-.*#%$4HG^)LCTNG^[]?"I_=OI^Y_P`=_(@VX`=0
M`NV47_RP"&2@$$Q>2#4#<=0?3_Y(](A'<F=0EM;YD<56&D(2XBY!S"5M=%'^
M6O1ATVW,S!.QU9"HB:54*,8N$XBNGZGU;^4/3-W9A(B<(;/4&4XDB(3ZGE41
M5-1`0HR(>J],]#$M[JNKF=S=W9A9ZY7`DGE$0P`PY"B<2'7'F'#,]`Z;W;Q=
MLJL]:49,N./?>B`&2V'A2R#JM21J,M#E>60#V;(<Z""U!"5SQLE!!@!W"B#(
MD*MRUK$(<,\Q8T%=+8E,`25)[[T"+C_#PX6H+@00<5&//C1A_D54PKA1P-!0
MJ4$%J<8)W?@R+QMRX+GAQM1F9>;2"0%.+,'/NY4LY1$!B2RCPM<NV-2,OUXG
M),1[J&E#?Q'9ZD9E0@0.N-S\,.^B%1#V1/94XR($E*!5:X)9E6QX/1/B]AGX
M84#MF)"EUR)!]U'S*5P!0*<['NHDVYA^`>_"C&\KHALZ$Y*AYX4\4;%OBK9D
M)DJ&BB&:*`2@.06UZ((3MV_/^N17S`%,1[^]O,R!*(B1(I@P6_/Q.+UJW(Q4
MX9*S$LI4\3X5(2+KD<A96_7C0B3Y/#@O!5]^)J(4K*R)AQ?#-%PHS$3J<@<S
MQ2Z/C6D[80W`+"RC!>=FQH@@Q'#$\4*IFQ'NH75%1#[<\AP`K2(V*>#*.Y2W
M?6I(ZL^Q6UDI8:P27%G2R%AA9B;@N:`!*(22EWPR7*DU%UMBRM@G/&U`HS'X
M_P!8MA[Z%,N%ERQ7#]%>C\?C7>5R^7W\N%1LJ?Y?EO05+X_!,<ZC>YOV]]8H
MA[9^#T;HV?#OH)4>QP]F?=45XWO;!/A@M#_4+]K^RC_I[\;\/UH)9/P__]H`
M"`$#`@8_`/\`G/78-$@QVYIH,=*I)91*D>\(Y%1,_MCHHH1`_P"WY3)+Q*E1
M)&(N=0&-;VW+[=Z(Z8`G3"P-BV)="+`5M_0^WNCB-P("8.X10IN`I!0OYB"0
M*/J'1*/2=5[D.(DEK"29M((Z@$#\(@@`$HI5`47VX<:8>7/C1-2<(/<J`\SD
MI(;,4BBRKA="&4J+HB'`T(")5K8W\+8A#8$E47"@X`X]N996?"M(4R0(0%'.
MX6UFN"*("AT4CG9%RN4"7J),45TQ#8W'M+J*#+0)#9Y^-K9.J-1_#H]S9BNU
M'9@HC$/$;<0PB3Y0Y(CYBBMYA6]Z=Z4?JQW8G0/-JVYQ<D`:2(,9`$#0N)-;
MD.HW8RW=[;C&8U>:(C=C\VIP""&+WJ4-_>E"$"FWLQ!$R4!#Q=T$0B1#DV?K
M)]1&1W8;01%0:9Q&DD@D>:1("J=)PJ)F0I>V#=NSL;>SLE$:"JDD1(U'^TJP
M1B7!XH]2E(>8V0DXWME=<Z0A*`+!;BZX$!"KI=A\Q!(HDR=[#LV&=3(W'!"7
M9T(07!%E>))EE4NSJP"HO`M?)ZC]4`%6`<1".-2N5)<`!"``5IP-!6P=^)_+
MN<T1%"$=G5SA?-</"E'RG)L3ASYV3DC:@Z7['&C*.UYHR)+DDAE`8A219U1`
M12$H%#G\@5YLWX=/O?NSMP^E#*3Z8N=1B"69_*"B8T/^2ZC5&<#&,YPTQUB2
M@QDL=1D!<J!8.AK?ZG<AIZ;;29D"H3,2LX=R,59%WI=/UHV=<BG^VHG$W.JS
MD6*.#C77;>[U!W)3B$4`$@%22DL$=`42P!)I%\JM0)NA1T'>72ZV6E(D=QV`
M8D?W:@QL"<+TQ.E"0N:E0UP`0@"A%)PH%&([&A,D1E$K\I*,0J!\<""<"BU&
M*+.Q((`<A;J4X*O>6VY2TG<(NA"8$!0H`5"H$B$$L$E$A0G(7`N'`Q4/W49&
M1D2,6*8$A!IY<[43C2J](1;BG;\ZB_E+'`H0A*_!%J,`).`Z*+A07!>ZH_B*
M,0)&28NS(20W!,Q9E_#:ZKHI0WNG$8#4D6EH!TX`'4K@9K=3U?4[VU]3JWA#
M"&V2^K-0"I/R@5O^DR]4ZG<Z78VX2A&<Y:9%%0@I\PBCL?*$%?NQTYCL;@&J
M*_*;Q^F+(2QB6B2H4@5UG2R/TY[L`814*0H5KEC9@V*)4#WXLO<MG85ICI")
MQ)6+,'C@75>:UF/A9N!7)T-0,T+Y6S.H6P4%C<DFM!!4EP$52I^#+[JU:O*H
M)*H``]R",@1D2A!%+J;/"RWXX>-#4@!/"P!D25NI4E`J'&]0DJZAX@Y+<)V2
MH1)\H.D!$&*#,D`I=#I4!5HJ$*`X]P'<[@$T2J"[V`9RHMBRE<&K1M@%,0YP
M56XO4F^50<U4/R0@CA?*M`BA!'-0'[[\EI08C_M>[>;/^W`*1<U\CIW61>2O
ME6Y#Z)WNB+&*N(FZ`@B_@40L*&[U/H<SN(@"``,!\I5D8DESWT=V/H6]]<@`
MGRN+I;/C:IZ?1MY=/E<(#>U@.``*NM?7ZF,=OIHL(!506N020MV%UN:)&0QR
MM?V@4D@5:[8,YMPL0;/1:Y[L@W?7$@*UT6^8!)0$]U*Z]K\O<UJ``2(P#`+R
M9_:]$@DJ$(4I?FGLLUJ<A`F'BV*8YBI`(]_!/8@`R#"U`B5N&14=C2D>;/&Z
MW_.@3\X5#SOW)\#A23`(>Z8HN%B@:S6K49>;/%,ERR%A=*216[8$$)^A%J)!
M0G$-D'1,`!R:E4WS/;NMC?\`H:EQJ]GX<^8PQHSA,?35BJ+@;NH"7'!5M$:5
M!![FQ=@5"',,:EY'.`SX#'/N6STX"LJ7'ZD.%J4BJASFF0S?)3=!1U1`.1/!
M#;Q7N"UIFAD"4B_-S=$Q4(KIC$%/<R)GA2)C@A8)BJ!72B)G3*YX!"6Q):P6
MO8AN#B$Q.(&#@U*/!C[R4)(1L^#K7E!TX$A`;!C8C%G!N$J.HA5S`[.42ZAC
M>D)"?G[T<?U%10E.!,K`*%7OYL2W*],NHA,.67_2$5>5Z4D(39^"X^"KPQHV
M1?@C<4SX(AH15<$MWY-QMFE2GM(B,4%T:05=6=[A@!3(2#\%"E;*_+!6J*`<
M@>"<01D%"(*!*HBWN2=*%F(O_I4X4$``1,N/>GM2B?!W8I:P&685Z$G3]"YM
MB2<PU&("E6R?DA=7)/<H>(!\O(17RJ5`Q+JF*)4SI"D>*V!%VLA)*D.,'*G^
ML]L.W^-2R;X]_;E4;7/*_O\`C073C94P^5/;@M\:X+C;NX\^YTJ%U0*M[>'+
M3A>C:YYW/S?#\JAR^/9>-21+8<N./+"U1^6YO;O^*\?P_.W;+C4\DPYB^*9\
M4K"QM>_N]M2MW=WS<?T_'__:``@!`0$&/P"UXUX=M6Z>+2OG57.8P8R6%Q-O
M(KP!,AT8/B]&AQ*\50'G3$C=<U4$0-51QQKE[/Q(P.8C;&2.DYX!0"=5&DBH
M++;"NJA()+MVIJ7KU#?7EWE!/J7Y+0/.V\@C=DQE`2CH#+1."C8N#O1-44RT
M3IQ7.7N0WOIE`21+D)+#;K;@ODGA<8,%0BT;T<51[Z:*BJG3O'7)"@UF;-=]
M726\2*,%O(F(S:+.C288//M,6\02\BF"-,O`NHBBIVU%=?37LJ=U1%T[IWT1
M?^WI2,D%$15555$1$3U7O^":]>V+`<OCE:2_<)R2UB=E(&R9K7^/<--UNMF<
MA6$58<H;*#59#80X:Q]6]Z/&:*:M+UHX0&2*6A`A"A"AD**@EW)$'3XD^$E7
M5.W4^55P)%K-BUTZ7%JHTF+">M)D5I'XE:S,F*,>*_8/-HR)NJ+(H:J:HB:]
M8_2>Z3V(^Y;B"SRQBQDXQ(&_XAS3&L@8IQC';C4Y/CF:.USTRJ:E`<B,XC3X
M-D)[5$M4J.5^)OY9'NJROC6^K(UQ1W]IF?!V'6.1T<P4>A76+XQD6>1I]Q"F
MLDALFI,DZTJ$**BIK-]OUI'Y!X`]QE=.LZN9P?[@<7<PO*#MZO<]+IZ>V:D6
M&/W=PRPX+OTK4M7W8Z>1ELP^-=Y$(KX_,H(6\D;7<HD*"FXT(1U31-5ZK9G.
MO(7VO)<B;W8CQGBU<>5\E9<7FV,I18G7^2P0)3Q#&1^4C$4GUV`XI]N@RSA7
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M4IF;<1CNOC0^N5O<!D;'W5KC3#I$Z)4M.`KU[D\XHU-C]0NICL:G9',;%]1^
M-&T)1W;5%>:?YB_N@?>Y(S3',Q:H\`D7P#95C'(CL$9MGDM)7/;X$.MX_JY<
M:LIX@IX(9HKH"+J;^A(C-34`_O%+7<+>S<6UP_[SYB'4D55[Z]<A<)<ETD.^
MPSD;&K7'K.)-;<=!E^;&48=G&4'&":M:R=XY,<VU$VS:U$DU5.N).(KS)F\Q
MM^-,$QS!G\F2,Y!"[3'H3<%BP&-YG78;C\"."&)Z[R'YB[KUEN?Y1+2OQ?"<
M;O,MR&<9@S])48[6R+:<]J3K)(2,15VZ+W+1/QZ]N_\`-VMY5O5\@>XGG:\S
M:+7.&C!<>8A1V,:W]KM=!CDR(POJ<)Q=]EXU4$5Z<VNA$X2EQ5S/B#OGQ_DO
M!J+,(J-`2)&=LXC26-2^VZ(N-R*NR!]@U)1VFTJ*B_T3D=JY4UPKNV!QIF7(
MCQC1ZTF`IHD1J4\R0.*@JJ#J7Q?AJB5YT]8W"2BR:)D5UC\3(IM_<1Z-B')A
MQKDZID9!5(U]JZVX\"?"C2$9(J(O25L9YA];)A8K44VA><?>-KQ*A,L"JHUH
M@('B%PB54VIJA:4?WBG=MK*H@M.VD+]3%"DT4DB,&/-1*3CF\HYKN>17B^)?
MS73CI6(R1?\`W.V56G99RU9<^WR!-I2=99*0`*0J1J.JIV1177HBU1-2VHI?
M-M%.PDI+JNBZJB?@B_U]99"XT%^5S7SW<U'M[X9J(6U;)[-N37':8[>K:(25
MY^FJ'WI2$.@-.@!DO9>J[V0__F;G$_CE.'Y'%=W:2/<-P63UW+MZ=^-D682F
MGI9$MM:9!)?L-Y:O(XX)(0DB:>X/V(<L"_CEW:).O*G%[`A<*HY+XQ<&KS&D
MCD`N1?-:8I(9E%L720,17P\FY21$0T-44D[#LT1"[#L[:;!5$_;Z_CU[454%
MDM+R]R,A`CA!Y-G&EFZO^81'=B:M:(BHJ:Z+I\*=<'<^\"<U\6YSQICO`G&M
MI<X,YP1$/D#C7CV5B56$&^I;<KVRA9J[A\=QI;(WXK#GC`I*!L`PZS'W/627
M7(OOX9NI,#GKD#E;(&LGR^%)N0=;J,AX\BLI&@8Q@&5X^V+,-8+*%')DXQ'H
M"HN?N5L<S9I^1^);B[1HU>1FGB94PR^^^X0JPHM64L%(B[+V551=$2340SA#
M:TG.');>0A'7P.+.M7X<N'(>`"[_`%E<ZV36O^'HOJB=(*?NHB>JJJ:(FFJJ
MJJJZ?GT6_0T+LHFJ$*(FG;:OPZ:K_P!_2JV@ZI\0;?3<NJ(JH"IJ**JZ_@GK
MUP[[%^'ZBVS/E'W<9U#C9%B>.W$.AN'N"^/I#64<DM.65DZ$&FBY+7P$K3F2
MR;BH+AH7J@KGOML3^6WFV!U$/&ZMSCVZ+GGA::W@UEQZS#EXG91:*KL5>EL0
M6:SPI#CDJN-JHIW).N3O:[DLH2N^&,D/-\'BRU<;E%@&<S)3=O5-09@H_%B8
MMFT>0WH`?PTF"/PIM1>LBHK!7JZ?!R>]C6,'RNMR8L@+`R<><,0\KP%$=%QL
M-0+0T^'MU!@USWVZF9<9LLBG^)IZUNA@!N2G=D'M\40E5&P90-Q(XNXM==:3
M(V\:PRKM;^YR.ON[.GI8\6SK(KA+'ARZZ2TI.,NUCLW>CK1!M4"5"7\'&+>2
MR[=0`<B1KXFA%^UB,./-C'MC$E=>=1I2-EQHE<=%4;+7XM,'FJJ35JAM[:R?
M:$$&+`8@'&??+5-4UE2$02U0D)>RZ]E>FV<N#6Q%`77Y-I)8@0&FVP)UQU9,
MMQD`V@XBEN(/E5=4[]8705O(F)WW"OLAXTRG(N/`*ZKPJ,]YZM7H-3?WN-NR
MY?BO#PB')\0/,*K:"V9`JIH72N(8>%Q$(C<$'XZ^3XC430R$M[:(J:%L0>Z^
MJ=<4^[#C+*Z>PLLD3"N9\IQBCNH#UU"ML,L!PW*Z>;`9DDU';SO#W#$0?%5D
M&+J)Z:CCW*7#F>8_F>)Y+7#95\BILV')581L@W+K;BO\Z3JFQ@2#5I]ET`V&
M&ORHA=>USCRJS3&[+.86?\B93-QBON:Z?:P<</"':!JYFQ(]@1PX<FSLFVF%
M=VDZJEL%=JZ>V*JQ_)L/SN*Q[>^/<+RBGCVM7<2(\JLP^)291C604H2)4IB5
M$>B/,2HS[6JBA;D4-5ZQ_F3B>).G^WSDB196&*ULETOM&1\96DY)/(W"MF_O
M%8V28#(?2;4/GJ2-+'V[55U%R+&L3Y`Q'D?B[F7#YV-74*DNHJ9#3?7Q?XL6
MVJEDK:4>48Y/9\B-2&Q<;?BH2:CWZS7A[W6U5F?M2YOLV!K.8J2`4[$RL*=[
M[;C7)3;K0.#"D2Z-X(M_5.(,B.J"\VCJ#VJ<VXWRO'LZQ"\@L3*C(\4MH-O2
MV45T4,)$>7!?D-HJ)JB@JHXG9%1%1=+'/>9\XIX%H,<DQKCNOL8<G.LVO48(
MHM-1U`O_`%#02"V@]+D-MQ(X:F9:H**U[I?=+R575:\R9?R%R[&<RO(JBMQO
MC?C:9=/QL/Q&HDOK#ALTM%35J+JA*;CQD6I*J)U[NO>7^LJ6PK.,<:QS@#VX
MXS,M(C%NSQW*?*7D6?PJM^4,[;EME#<`74`4('1$M2T52?DR&V19%4==F*VQ
M&2.J*F]P9#P-EY2<V!M,5<(=%54%>LVOZ++Z,>#+3,B;S]JEMXUQ'I.,^<:]
MN]O*QQJ&\Z:O\?9BOW%8XZOMML;?WA#K_5K_`%@XT_TQ6H3)O]0OUI0_I1:)
M&U<^M2V^N^D6.D==%'YT=5`TWKKTF65-N_AV9D$89L^+$2559`<1M0A.7<('
M&G')D0341=!2=4045545>GXL;D3%!!]=Q;X5V".*CR.B>FKB@.]Q5311T7]B
M:=-QUS_$U!HG%39$O!>$'0;U!MQSRZ:EHGXHOS*F[IMV?R#B1-KHLA!K+J2I
M;$-4=`%=05>0"5/B^+7MKIIU,^VRYF0Y5=-1UN\DLXXL2Y:161$(=>PTTH5E
M4;Q*1-BNBEW7OZ,X3S)@]3R!BP6;%X%%>.SE@.64!LVV)#S41^*DA1:>)%;<
M(FC15U1>F\>_Z7^!VWZEAJ1&C4F,4U3<1(KO\)'D>HBA7$>*J_P]QF@$OP]_
M3IG&0C,LXU&HV\;;K-#\24@P1JAK3<(U<2,D$`;U14/1.Y?CU)^E]J?"TEYY
M-CTNUQ6+DDTQT117[A?K9S&2)M15$%W<@DO?15UG9SQCP!QQ@.4VE-<8Y9VF
M)TQ4*S*+((PP[NO=AU<B)`(;","`1JTIBB?"J+T:UOM1X2<=EHVVX_<X9#O9
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M5-_8E3]O?K#,<Y$X.X[RK&>.HST/",5GT;08ICT5\FS<8AXS%6/1>(C9%4`X
M[@MJBJ.FJZT&2UWMAX?H[_&+*!<4=KCN*Q\=FP+*NE-S8LE'Z(ZTI2L2FA,$
M>0PW)W%=53K(L!SVBAY-A^65[M;D5%..2U$MHCK@F<=XHKK4B,V9`BDK)@2D
MJKZ^KD:![3^#-CI..NOS\#J+:<\\XJ>0WY]FQ+GOD[IJ9$\JDJ)KKHFB1O\`
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MX@>><!%5M-!UZF<ANSF9>')BLG,`L4;7Z9_'UKGK%MS0Q;/5^!M`FE!71<<T
M5/RPQF\J\@A6G.'(%C/G7D"D*;BM'E&429#N-8)*N"=`5LX-.#+>QEMT63U$
M^^O4BUOK=BJKXC[4;S2'-_U$R5(5B%`C,`P_*D29CP;0::0C7<J"G9%3-,.I
MJO)FI6!QZH,BL;NG2J@P[6S9.4Q2BVX:2W[9(*)(=T`6FF'`5=%W)UD6-1VL
MKR"UQS'V<@2-C^.R;:3DT5Y7VA'%6HXB=FK1Q7"==4&V$$25"TTZA<A7)W,2
MHL*=;V%5'3.CDTB+]*LXXA5#@B<>9%B@JO(:H#0ZD9BFWK`HXN9.W&Y%@R9E
M!;E0J[2?6Q8XO/XX4EA2=EWH.&+",QD>%))(VIDJ*G606>/Q,@K/TOD=EBEU
M`OZP*RQB6M4C9R1)D_,TVFQ>^\TV*NBCN5$3)K"]FV4Q<1JV;C((./U1W$NG
MB2WT"`EIX_'&@OVB$B1FG'0=)%W$*)W6FMR@6-8Y<5\6R2IN&66K*$,F,+K<
M*P^D)V-%F;>[B;C03U%/PT_V4)5+0-25!540M!7L2)W)._I^*]76/X)3W5@=
M]:4%3E+6,0QL+Z-A<JS;3)9-77`HG.D%7LFUL;4C4371.W6!7DS%9&!<6<25
MSS/%O'M@P+=]-O9D1N&[F.61&'I+4!Z)&-X(D0S-[R.$^[M/:*85"_1MG)X]
MXPK8>6PKVU\$7%K[D&>\<4)ME,80I]FN'4ZG]'$!M46:Z)+H(;TX(S^9CF0Y
ME@O'\G,;:PI<<KEMKB-FTBG;;PZP>J8@`ZZWYMX`ZJHS&=5"=4!7<O+7,_*K
M$6AS#E"Y>S"]IFYX6+&$X3B]>L?'<;?DM(3$BQ@T[1NS3:U:1]U4$ET37EIF
MEQ7(Z_.?=AF,NXL<LNZU]O#L2X?>)FIJ)S%QJD6RE,8BR^,2$P*R2F2OX@BV
M/D7"^!^.X%P=5D5IA''5]>1/I_\`ZWQO4(R_DEO:/."3K!V556I%^%LC1Z6B
MHB(BEUQ7'B\>7O&G%/`MC:SZBCRVOB5MQD>9T[3N.XK+K(D.5*<_3-76./S5
ME.$)SGY`#HGC(NLLL:GC?(LQKL(XU8L^)GWV(K6#Q\QL0E/9';V+QN_4V.5L
M1D:A0666R<!I"%-OD5SIZ3G=-95N6Y?:R\URB7>&Q^J;W([HWGKA^SKHSKT6
MHAQ%%J/"8!POX`?$+>X@3DWFO.<?>I<UY*R-YBJHI2-#,Q/C^H=<B44%X`-U
MAJ9:!'^H?`$%?B1/5.L/X?HZJUC8EF=DK_)V=Q1BL,4N#5:A(FXZS(>(G$L\
MH=!MDD$=/")*NG;KD?F.IXPM@L^+Z-SBCVP<>LP(T^5353>R%8\C#7LRC)R5
M-,R=84G"<5AM%^$EZFUF.XL7ZTJ,>M;BFJ7YI6ESD&76,9RRDVV0"7^4.[GW
M3ANK&;=?%K:((XO?3@W!I?$V8,X'+>+D[E!W*3@,7&9<EU3@2#7D>V2P?9HL
M><MG$?9C_P`9YZ*P@^)$%MOIE9``$A6P\PMKN:1Q$^)&BT1590M=FNB[=-=%
MU_VU^?\`OV-?%OW_`+O]6W;ZZ?NZ_CTW^?A=TV^?3;IWW:=MO^_XM=-.F]-F
MF\O77PZ[Q^77XMVGI^&[7\=.BT\7^#KX]WG^=/[W=_@:>FG[>N8/I/OVS]"7
MOU'Z<^P?5>#PO>7[I][_`,Q]ATU^J^E_S'@\OC[[>N./_C?'^@<6T^Q:_8_'
M^G(FGV;_`-5]/KKMW?Q?77MMZ/39IL9_YFW31W3R[_BV;OR[_GVZ+^UJ&_;Y
M-V[Q-Z:?X/BT^;9\.[3\>EW>GG;]?77]S9XOB\_]G\-GS=.Z_P!ESY]=FFQS
M3Z?;W\G_`#/WM=?V==M_H/S[M?D'^UW_`-_[=>CU\OJFNWRZ^J>FS_"U]=/Q
MZ:UV:=M/G\?SAKLV_%]5Z?-^[_Q='Z[MB_W>FW;Y#T\.G\/33_B_/OTYN^F_
F\VUM^HV:;-&?3Q]_J=?[G?\`'Z_AT/S?*GS:[O1/FU[[OS_H_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
